Summit Therapeutics to test ivonescimab with AstraZeneca-Daiichi ADC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. TMUS
10. VZ

Go back to Summit Therapeutics to test ivonescimab with AstraZeneca-Daiichi ADC

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

October 2, 2026 2:30 AM EDT

Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer

MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings,... More